SAN FRANCISCO — McKesson Ventures, the venture capital arm of McKesson Corporation, announces the expansion of its leadership team, promoting Jennifer Carter and Carrie Hurwitz Williams to partners of McKesson Ventures. The new partner roles exemplify McKesson Ventures’ growth since it was established in 2014.

As partner, Carter and Williams will identify long-term strategic industry opportunities, invest in healthcare technology companies and build valuable partnerships with McKesson Ventures’ portfolio companies. Their promotions underscore McKesson Ventures’ commitment to an apprentice model of mentoring and promoting from within.

Carter has over 20 years of health care experience and her expertise spans marketing, business development and sales operations. Carter joined McKesson Ventures in 2014 as vice president of portfolio development and is responsible for identifying and evaluating commercial synergies with portfolio companies and McKesson. In 2019, Carter expanded her role to oversee operations for the firm which include managing talent, budget and resources. As partner, Carter will take on direct investments and board responsibilities within select companies in addition to her current role.

“With my background and experience at McKesson, I’m interested in companies that are pushing the boundaries of pharmacy care and are finding ways to improve access, adherence and the overall patient experience,” said Carter. “I’m excited to have the opportunity to work closely with entrepreneurs and provide them with support and guidance as they grow their businesses.”

Williams joined McKesson Ventures in 2017 as principal and brings over 15 years of experience from across the healthcare industry. Williams’ operational and strategic mindset draws upon prior experience with managing clinical trial operations within pharmaceutical and biopharma settings, various roles within McKesson’s strategy and business development team and as vice president of strategy and business development at Omada Health, with a focus on commercial strategy and partnerships.

“I’m naturally drawn to companies that are at the intersection of drug development and technology and companies using technology to enhance patient engagement, care and improve their healthcare outcomes,” said Williams. “The patient is at the forefront of what we do, so to be able to lead and make investments in this area is a privilege.”

As partner, Williams will continue to pinpoint strong investment opportunities with a focus on healthcare tech companies on the east coast. Some of Williams’ investments include Propeller Health, a digital health company using connected sensors to help manage chronic respiratory diseases and Xealth, a digital platform that enables clinicians to easily integrate, prescribe and monitor digital health tools for patients.

McKesson Ventures continues to establish itself as a leading investor in high-growth companies that are focused on optimizing life-sciences data, technology and services. Additionally, McKesson Ventures continues to strengthen its presence and expertise in oncology care, consumer health, digital pharmacy, digital supply chain and value-based care.

Most recently, McKesson Ventures led the Series B financing for Lightship, a global direct-to-patient clinical trial company; participated in the Series D financing for Evidation Health (led by Williams), a platform that powers research to measure health in everyday life to understand disease outside of the clinic; and has supported the successful IPO launch for Accolade (NYSE: ACCD), a benefit steerage platform selling to self-insured employers.